Methods for county-level estimation of pre-exposure prophylaxis coverage and application to the U.S. Ending the HIV Epidemic jurisdictions.


Journal

Annals of epidemiology
ISSN: 1873-2585
Titre abrégé: Ann Epidemiol
Pays: United States
ID NLM: 9100013

Informations de publication

Date de publication:
04 2020
Historique:
received: 04 11 2019
revised: 27 12 2019
accepted: 05 01 2020
pubmed: 24 2 2020
medline: 8 9 2020
entrez: 24 2 2020
Statut: ppublish

Résumé

Pre-exposure prophylaxis (PrEP) is a pillar of the US Department of Health and Human Services "Ending the HIV Epidemic" (EHE) initiative in 50 EHE jurisdictions (48 U.S. counties and two U.S. cities) and seven U.S. states with high numbers of HIV diagnoses rates in rural areas. Current data systems do not provide data on PrEP uptake in counties or cities. We report on PrEP users at the county level. Data from a large, commercial pharmacy database were used; we applied the U.S. Census Bureau's method to allocate PrEP users within a ZIP3 into counties and validated the results. We report counts and rates of PrEP users in 2018 for all EHE jurisdictions. We used joinpoint regression to model the estimated annual percent change in PrEP use for each jurisdiction and state. 93,156 people in the 50 EHE jurisdictions used PrEP in 2018; 94% were men and 39% were aged 25-34 years. There was more than an 80-fold difference in the range of rates of PrEP use per 100,000 population among the EHE jurisdictions (range: 8-644 per 100,000 population; median 93 per 100,000 population). PrEP use increased from 2012 to 2018 in all EHE counties and states. At current rates of growth of PrEP use, 94% of EHE counties and jurisdictions will reach their National HIV/AIDS Strategy goals of a 500% increase in PrEP use in 2020. EHE states had less variation in rates of PrEP use (range: 29-51/100,000 population; median 32/100,000 population). At the outset of a major U.S. government program to reduce HIV infections, rates of PrEP use are highly variable among the 50 EHE jurisdictions. Data from commercial prescription databases will be a useful public resource to understand progress in promoting use of PrEP as part of the EHE initiative and evaluating progress in PrEP use across health jurisdictions.

Identifiants

pubmed: 32088073
pii: S1047-2797(19)30816-6
doi: 10.1016/j.annepidem.2020.01.004
pii:
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

16-30

Subventions

Organisme : NIAID NIH HHS
ID : P30 AI050409
Pays : United States

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Patrick S Sullivan (PS)

Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA.

Farah Mouhanna (F)

Department of Epidemiology, Milken Institute School of Public Health, George Washington University, Washington, DC; Department of Behavioral Science and Health Education, Rollins School of Public Health, Emory University, Atlanta, GA.

Robertino Mera (R)

Gilead Sciences, Foster City, CA.

Elizabeth Pembleton (E)

Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA.

Amanda D Castel (AD)

Department of Epidemiology, Milken Institute School of Public Health, George Washington University, Washington, DC.

Chandni Jaggi (C)

Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA.

Jeb Jones (J)

Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA.

Michael R Kramer (MR)

Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA.

Pema McGuinness (P)

Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA.

Scott McCallister (S)

Gilead Sciences, Foster City, CA.

Aaron J Siegler (AJ)

Department of Behavioral Science and Health Education, Rollins School of Public Health, Emory University, Atlanta, GA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH